News | June 29, 2024
Aurobindo Pharma’s subsidiary acquires Ace Laboratories, UK
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
